Please assess the completion status of the following clinical trial:

Trial Title: Pulmonary Artery Denervation for Treatment of Pulmonary Arterial Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with pulmonary artery hypertension (group 1 of the Nice classification of pulmonary hypertension)~  * Aged over 18 years old~ * NYHA class III or IV~ * Not controlled by optimal medical management as defined by:~    * dual therapy including a prostacyclin.~   * or dual therapy including an endothelin receptor antagonist and a~ * 5-phosphodiesterase inhibitors, in patients with contra-indication of prostacyclin, poor tolerance to this treatment, prostacyclin derivative treatment failure or patient refusal.~ * Valid status in the social security system~ * Signed informed consent~Exclusion Criteria:~* Patient eligible for pulmonary transplantation~* Pregnancy or breastfeeding~* Adults of the age of majority subject to guardianship court order or deprived of liberty~* Patient with history of radio frequency procedure~* Known heparin allergy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- denervation (Type: EXPERIMENTAL): None
- control group (Type: SHAM_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).